Navigation Links
Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010
Date:1/31/2011

AUSTIN, Texas, Jan. 31, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, will host a web cast and conference call to give a company update following issuance of the fourth quarter financial results on Thursday, February 10, 2011.

Conference Call Information

To access the live conference call via phone, dial (800) 920-4872 from the United States and Canada or +1 212 231-2900 internationally. The conference ID is 21509979.  Please dial-in approximately ten minutes prior to the start of the call. You may also access the live and subsequently archived web cast of the conference call from the Investor Relations section of the Company's website at http://www.vermillion.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

A telephone replay of the call will be available beginning approximately one hour after the call through February 25, 2011, and may be accessed by dialing (800) 633-8284 from the United States and Canada or +1 402 977-9140 internationally. The replay passcode is 21509979.  An archived replay of the web cast will be available until the next quarterly call.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1™

OVA1™ is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. OVA1™ is a trademark of Vermillion, Inc.  Additional information about OVA1™ can be found on the Web at www.ova-1.com.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at www.sec.gov.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
2. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
3. Vermillion Reports Financial Results for the Third Quarter 2010
4. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
5. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
6. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
7. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
8. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
9. Vermillion Announces the Reappointment of Officers and Confirmation of Director
10. Vermillion Announces $43.05 Million Private Placement of Common Stock
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology:
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of America ... with a reputable physician in their area, announces the launch of a new and ... patients who are looking for reputable physicians to help them with back or neck ...
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common ... issue of Consumer Reports focused on heart health. , The magazine gave ... coronary bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after thirteen ... in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl appearances ... yards by a quarterback (6,109) and the most rushing yards by a quarterback in ...
(Date:4/24/2017)... San Antonio, TX (PRWEB) , ... April 24, 2017 , ... ... sky-high by the glitterati, those unreal icons inhabiting the rarified air of pop and ... by the paparazzi and anyone snapping pictures: the smile. Grins now run the gamut ...
Breaking Medicine News(10 mins):